|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1993-6-23
|
|
pubmed:abstractText |
Orally administered all-trans-retinoic acid (all-trans-RA) can induce complete remission in a high proportion of patients with acute promyelocytic leukemia. A previous pharmacokinetic study in patients with acute promyelocytic leukemia raised the possibility that the absorption of orally administered all-trans-RA is a saturable process that would have significant clinical impact on dosing strategies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
993-6
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8388479-Adenocarcinoma,
pubmed-meshheading:8388479-Administration, Oral,
pubmed-meshheading:8388479-Adult,
pubmed-meshheading:8388479-Aged,
pubmed-meshheading:8388479-Biological Availability,
pubmed-meshheading:8388479-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:8388479-Carcinoma, Squamous Cell,
pubmed-meshheading:8388479-Chromatography, High Pressure Liquid,
pubmed-meshheading:8388479-Colorectal Neoplasms,
pubmed-meshheading:8388479-Dose-Response Relationship, Drug,
pubmed-meshheading:8388479-Esophageal Neoplasms,
pubmed-meshheading:8388479-Female,
pubmed-meshheading:8388479-Half-Life,
pubmed-meshheading:8388479-Humans,
pubmed-meshheading:8388479-Intestinal Absorption,
pubmed-meshheading:8388479-Lung Neoplasms,
pubmed-meshheading:8388479-Male,
pubmed-meshheading:8388479-Middle Aged,
pubmed-meshheading:8388479-Skin Neoplasms,
pubmed-meshheading:8388479-Time Factors,
pubmed-meshheading:8388479-Tretinoin
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Variability in the oral bioavailability of all-trans-retinoic acid.
|
|
pubmed:affiliation |
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Clinical Trial, Phase I
|
